Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 20, Issue 6, 2007, Pages 447-457

  Kumar, Amit ^a   Cannon, Christopher P ^b  

^a UMass Marlborough Health System   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ATHEROMA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MYALGIA; MYOPATHY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PRAVASTATIN; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; SULFONAMIDES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 36549068675     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00298.x     Document Type: Review

References (29)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994 344 (8934 1383 1389.
2. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
3. Cohen M, Antman EM, Murphy SA, Radley D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. Am Heart J 2002 143 (1 63 69.
4. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001 285 (13 1711 1718.
5. Cannon, CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 (15 1495 1504.
6. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: Results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005 46 (8 1405 1410.
7. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: A comparison of the postacute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006 113 (11 1406 1414.
8. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004 292 (11 1307 1316.
9. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 (14 1425 1435.
10. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005 294 (19 2437 2445.
11. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006 48 (3 438 445.
12. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006 47 (11 2326 2331.
13. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002 287 (24 3215 3222.
14. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002 105 (6 691 696.
15. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003 107 (13 1750 1756.
16. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: Could it be the pleiotropic effects? Am J Cardiol 2005 96 (5A F54 - F60.
17. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003 108 (14 1664 1672.
18. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation 2003 108 (15 1772 1778.
19. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 (23 Suppl 1 III39 III43.
20. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005 46 (8 1425 1433.
21. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 (1 20 28.
22. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dL and C-reactive protein <2 mg/L: An analysis of the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005 45 (10 1644 1648.
23. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005 46 (8 1417 1424.
24. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005 46 (8 1411 1416.
25. LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007;100(5):747-752.
26. Barter P, Gotto AM, La Rosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New Engl J Med 2007;357:1301-1310.
27. Ballantyne CM. Clinical trial end-points: Angiograms, events, and plaque instability. Am J Cardiol 1998 82 (6A M5-M11.
28. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004 291 (9 1071 1080.
29. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006 295 (13 1556 1565.